Lichti-Kaiser Kristin, Brobst Dan, Xu Chenshu, Staudinger Jeff L
Department of Pharmacology and Toxicology, University of Kansas, Lawrence, 66045, USA.
J Pharmacol Exp Ther. 2009 Oct;331(1):65-76. doi: 10.1124/jpet.109.157180. Epub 2009 Jul 17.
The pregnane X receptor (PXR, NR1I2) regulates the expression of genes that encode drug-metabolizing enzymes and drug transporter proteins in liver and intestine. Understanding the molecular mechanisms that modulate PXR activity is therefore critical for the development of effective therapeutic strategies. Several recent studies have implicated the activation of kinase signaling pathways in the regulation of PXR biological activity, although direct evidence and molecular mechanisms are currently lacking. We therefore sought to characterize potential phosphorylation sites within the PXR protein by use of a rational, comprehensive, and systematic site-directed mutagenesis approach to generate phosphomimetic mutations (Ser/Thr --> Asp) and phospho-deficient mutations (Ser/Thr --> Ala) at 18 predicted consensus kinase recognition sequences in the human PXR protein. Here, we identify amino acid residues Ser8, Thr57, Ser208, Ser305, Ser350, and Thr408 as being critical for biological activity of the PXR protein. Mutations at positions 57 and 408 abolish ligand-inducible PXR activity. Mutations in the extreme N terminus and in the PXR ligand-binding domain at positions Ser8, Ser305, Ser350, and Thr408 decrease the ability of PXR to form heterodimers with retinoid X receptor alpha. Mutations at positions Ser208, Ser305, Ser350, and Thr408 alter PXR-protein cofactor interactions. Finally, the subcellular localization of the PXR protein is profoundly affected by mutations at position Thr408. These data suggest that PXR activity can potentially be regulated by phosphorylation at specific amino acid residues within several predicted consensus kinase recognition sequences to differentially affect PXR biological activity.
孕烷X受体(PXR,NR1I2)可调节肝脏和肠道中编码药物代谢酶及药物转运蛋白的基因的表达。因此,了解调节PXR活性的分子机制对于开发有效的治疗策略至关重要。最近的几项研究表明,激酶信号通路的激活参与了PXR生物学活性的调节,尽管目前缺乏直接证据和分子机制。因此,我们试图通过一种合理、全面且系统的定点诱变方法来鉴定PXR蛋白内潜在的磷酸化位点,以在人PXR蛋白的18个预测的共有激酶识别序列处产生模拟磷酸化突变(丝氨酸/苏氨酸→天冬氨酸)和磷酸化缺陷突变(丝氨酸/苏氨酸→丙氨酸)。在此,我们确定氨基酸残基Ser8、Thr57、Ser208、Ser305、Ser350和Thr408对PXR蛋白的生物学活性至关重要。第57位和第408位的突变消除了配体诱导的PXR活性。Ser8、Ser305、Ser350和Thr408位的极端N端和PXR配体结合域中的突变降低了PXR与视黄酸X受体α形成异二聚体的能力。Ser208、Ser305、Ser350和Thr408位的突变改变了PXR与蛋白辅因子的相互作用。最后,PXR蛋白的亚细胞定位受到第408位突变的深刻影响。这些数据表明,PXR活性可能通过在几个预测的共有激酶识别序列内的特定氨基酸残基处的磷酸化来调节,从而差异性地影响PXR的生物学活性。